

Global Acceptance of Biosimilars: Importance of Regulatory Trust

Oncologist

23, 1188-1198

DOI: [10.1634/theoncologist.2017-0671](https://doi.org/10.1634/theoncologist.2017-0671)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars. <i>Pharmaceutics</i> , 2018, 10, 168.	2.0	12
2	An Empirical Analysis of the Perceived Challenges and Benefits of Introducing Biosimilars in Bangladesh: A Paradigm Shift. <i>Biomolecules</i> , 2018, 8, 89.	1.8	4
3	Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review. <i>Clinical Therapeutics</i> , 2019, 41, 155-173.e13.	1.1	30
4	Clinical and Regulatory Concerns of Biosimilars: A Review of Literature. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 5800.	1.2	28
5	Biosimilar Drug Development. , 2020, , 1-24.		0
6	A randomized phase I clinical trial comparing the pharmacokinetic, safety, and immunogenicity of potential biosimilar recombinant human HER2 monoclonal antibody for injection and trastuzumab in healthy Chinese adults. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 755-762.	1.9	8
7	ChromaTech: A discontinuous Galerkin spectral element simulator for preparative liquid chromatography. <i>Computers and Chemical Engineering</i> , 2020, 141, 107012.	2.0	13
8	Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars. <i>Journal of Clinical Oncology</i> , 2020, 38, 1070-1080.	0.8	19
9	The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. <i>Drugs</i> , 2020, 80, 99-113.	4.9	58
10	International Society of Oncology Pharmacy Practitioners global position on the use of biosimilars in cancer treatment and supportive care. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 3-10.	0.5	6
11	How do biosimilars sustain value, affordability, and access to oncology care?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 327-329.	0.7	9
12	Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria. <i>Pharmaceutics</i> , 2021, 14, 64.	1.7	8
13	Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. <i>MAbs</i> , 2021, 13, 1868078.	2.6	17
14	Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice. <i>British Journal of Cancer</i> , 2021, 124, 1346-1352.	2.9	16
15	Biyobenzer A'la'Ålar. <i>Beykent A'cniversitesi Fen Ve M'Ahendislik Bilimleri Dergisi</i> , 0, , .	0.4	0
16	Informing Patients about Biosimilar Medicines: The Role of European Patient Associations. <i>Pharmaceutics</i> , 2021, 14, 117.	1.7	30
17	Analysis of the Regulatory Science Applied to a Single Portfolio of Eight Biosimilar Product Approvals by Four Key Regulatory Authorities. <i>Pharmaceutics</i> , 2021, 14, 306.	1.7	1
18	Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects. <i>RMD Open</i> , 2021, 7, e001637.	1.8	12

#	ARTICLE	IF	CITATIONS
19	Challenges Faced by the Biopharmaceutical Industry in the Development and Marketing Authorization of Biosimilar Medicines in BRICS-TM Countries: An Exploratory Study. <i>Pharmaceutical Medicine</i> , 2021, 35, 235-251.	1.0	8
20	Meta-analysis of Pharmacokinetic/Pharmacodynamic Results of 3 Phase 1 Studies with Biosimilar Pegfilgrastim. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 1130-1141.	0.8	3
21	Current and future roles of biosimilars in oncology practice (Review). <i>Oncology Letters</i> , 2020, 19, 45-51.	0.8	13
22	A narrative review of biosimilars: a continued journey from the scientific evidence to practice implementation. <i>Translational Lung Cancer Research</i> , 2020, 9, 2113-2119.	1.3	0
23	A narrative review of biosimilars: a continued journey from the scientific evidence to practice implementation. <i>Translational Lung Cancer Research</i> , 2020, 9, 2113-2119.	1.3	5
24	An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review. <i>Ophthalmology and Therapy</i> , 2022, 11, 959-982.	1.0	12
25	Anti-rheumatoid drugs advancements: New insights into the molecular treatment of rheumatoid arthritis. <i>Biomedicine and Pharmacotherapy</i> , 2022, 151, 113126.	2.5	35
26	Practical Strategies for Advanced Practitioners Streamlining the Integration of Oncology Biosimilar Therapies Into Practice. <i>Journal of the Advanced Practitioner in Oncology</i> , 2022, 13, 417-439.	0.2	0
27	Nurses' Knowledge and Attitudes towards Biosimilar Medicines as Part of Evidence-Based Nursing Practice—International Pilot Study within the Project Biosimilars Nurses Guide Version 2.0. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 10311.	1.2	0
28	Biosimilar Drug Development. , 2022, , 1237-1260.		0
29	Modeling Patient Perceptions About Generic Drug Quality and Trust With Doctors: An Empirical Analysis for Creating Sustainable Healthcare. <i>IEEE Transactions on Engineering Management</i> , 2022, , 1-20.	2.4	0
30	The Global Landscape of Manufacturers of Follow-on Biologics: An Overview of Five Major Biosimilar Markets and 15 Countries. <i>BioDrugs</i> , 2023, 37, 235-245.	2.2	3